Allo HSCT: Improvements in Transplant Outcomes, Myeloablative Vs. Reduced-Intensity HCT for AML and MDS, Optimal Haplo Donor
By
Indy Hematology Review
FEATURING
Richard Childs
By
Indy Hematology Review
FEATURING
Richard Childs
Login to view comments.
Click here to Login
